Synapsoft logo
AI Insights from Disclosures
Searching...
Voronoi, Inc. 310210
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Voronoi, Inc. is a drug development company that focuses on early-stage clinical development (Phase 1 to Phase 2) of its self-developed pipeline, concentrating mainly on the development of targeted therapies for oncology indications such as lung cancer and breast cancer. Through its in-house medicinal chemistry institute, bio institute, animal testing center, and AI institute, the company directly conducts early-stage clinical trials using its self-developed candidate substances to verify efficacy in humans, and pursues a business model of global technology out-licensing (License-Out, L/O).
Representative Director Kim Hyeontae
Founded February 24, 2015
Corporation Type KOSDAQ
Industry Classification Research and experimental development on natural sciences and engineering
Corporate number 13481-0326191
Business number 340-81-00023
Phone Number 032-830-4855
Fax Number 032-830-4856
Website voronoi.io
Company Address 32 Songdogwahak-ro, Yeonsu-gu, Incheon
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant